NASDAQ · SHPH
Healthcare · Drug Manufacturers - Specialty & Generic
$5.21
Up+$0.06 (+1.17%)
Updated Nov 5, 2026, 5:40 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SHPH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
SHPH closed at $5.21 after 21 trading sessions, up 10.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $5.07 | $5.39 | $5.07 | $5.21 | 14.75K |
| Nov 3, 2026 | $4.53 | $5.15 | $4.48 | $5.15 | 54.61K |
| Nov 2, 2026 | $5.15 | $5.23 | $4.75 | $4.95 | 92.21K |
| Oct 30, 2026 | $5.35 | $5.415 | $4.80 | $5.15 | 20.48K |
| Oct 29, 2026 | $5.285 | $5.3817 | $5.23 | $5.23 | 5.55K |
| Oct 28, 2026 | $5.12 | $5.5999 | $5.12 | $5.24 | 16.92K |
| Oct 27, 2026 | $5.05 | $5.295 | $5.05 | $5.21 | 10.35K |
| Oct 26, 2026 | $4.92 | $5.19 | $4.89 | $5.045 | 15.44K |
| Oct 23, 2026 | $4.55 | $5.18 | $3.30 | $4.86 | 191.11K |
| Oct 22, 2026 | $4.72 | $4.87 | $4.5501 | $4.61 | 9.69K |
| Oct 21, 2026 | $4.79 | $4.95 | $4.76 | $4.82 | 6.56K |
| Oct 20, 2026 | $4.755 | $4.915 | $4.70 | $4.91 | 6.64K |
| Oct 19, 2026 | $5.07 | $5.07 | $4.71 | $4.72 | 14.81K |
| Oct 16, 2026 | $5.2035 | $5.395 | $5.06 | $5.08 | 12.7K |
| Oct 15, 2026 | $5.25 | $5.68 | $5.25 | $5.57 | 35.12K |
| Oct 14, 2026 | $5.14 | $5.355 | $4.83 | $5.24 | 42.43K |
| Oct 13, 2026 | $5.44 | $5.56 | $5.045 | $5.18 | 22.12K |
| Oct 12, 2026 | $5.36 | $5.645 | $5.36 | $5.45 | 21.39K |
| Oct 9, 2026 | $5.32 | $5.47 | $5.11 | $5.33 | 29.45K |
| Oct 8, 2026 | $4.90 | $5.75 | $4.81 | $5.55 | 282.5K |
| Oct 7, 2026 | $4.01 | $4.75 | $4.01 | $4.71 | 119.26K |
The latest Smart Investors Daily articles mentioning SHPH.
Company
Market Activity
Research & News
SHPH research
Company profile and research snapshot.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 24, 2026
Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(3.10) per share. This is a 90.58 percent increase over losses of $(32.90) per share from the same period last year.
Benzinga · Aug 3, 2026
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding (NASDAQ:SLBT)
Benzinga · Aug 3, 2026
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus Pharmaceuticals
Benzinga · Jul 31, 2026
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is at
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SHPH.
